Table 6.

Adjuvant therapy with trastuzumab by age

Age category, years	Patients receiving trastuzumaba, n (%)
20–29 (n = 3)	2 (66.7)
30–39 (n = 30)	27 (90.0)
40–49 (n = 89)	67 (75.3)
50–59 (n = 116)	90 (77.6)
60–69 (n = 139)	106 (76.3)
70–79 (n = 53)	40 (75.5)
80–89 (n = 3)	2 (66.7)
90–99 (n = 0)	0 (0)
Total (n = 433)	334 (77.1

^aPercentage of those with HER2-positive breast cancer > 1 cm and chemotherapy.